Division of Molecular Pharmacology, Department of Pharmacology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan.
Department of Functional Genomics, Graduate School of Pharmaceutical Sciences, Himeji Dokkyo University, Hyogo 670-8524, Japan.
Eur J Pharmacol. 2015 Oct 15;765:291-9. doi: 10.1016/j.ejphar.2015.08.043. Epub 2015 Aug 28.
Only limited information is available on agonist-dependent changes in the subcellular localization of vasopressin V1B receptors. Our radioligand binding study of membrane preparations and intact cells revealed that a large fraction of the V1B receptor is located in the cytoplasm in unstimulated CHO cells, which is in contrast to the plasma membrane localization of the V1A and V2 receptors. Moreover, when the affinity of radiolabeled arginine-vasopressin ([3H]AVP) was compared between membrane preparations and intact cells, the affinity of [3H]AVP to the cell surface V1B receptors, but not the V1A receptors, was significantly reduced. Although the number and affinity of cell surface V1B receptors decreased, they became extensively internalized upon binding with [3H]AVP. Approximately 87% of cell surface-bound [3H]AVP was internalized and became resistant to acid wash during incubation with 1 nM [3H]AVP. By contrast, less ligand (35%) was internalized in the cells expressing the V1A receptor. Extensive internalization of the V1B receptors was partially attenuated by inhibitors of cytoskeletal proteins, siRNA against β-arrestin 2, or the removal of sodium chloride from the extracellular buffer, indicating that this internalization involves clathrin-coated pits. Together, these results indicate that the mechanism that regulates the number and affinity of V1B receptors in the plasma membrane is markedly distinct from the corresponding mechanisms for the V1A and V2 receptors and plays a critical role under stress conditions, when vasopressin release is augmented.
仅有有限的信息可用于研究血管加压素 V1B 受体的激动剂依赖性的亚细胞定位变化。我们对膜制剂和完整细胞的放射性配体结合研究表明,在未受刺激的 CHO 细胞中,大量 V1B 受体位于细胞质中,这与 V1A 和 V2 受体的质膜定位形成对比。此外,当比较膜制剂和完整细胞之间放射性标记的精氨酸血管加压素 ([3H]AVP) 的亲和力时,[3H]AVP 与细胞表面 V1B 受体的亲和力(而非 V1A 受体)显著降低。尽管细胞表面 V1B 受体的数量和亲和力降低,但它们在与 [3H]AVP 结合后会广泛内化。约 87%的细胞表面结合的 [3H]AVP 被内化,并在与 1 nM [3H]AVP 孵育期间对酸洗脱具有抗性。相比之下,在表达 V1A 受体的细胞中,较少的配体(35%)被内化。细胞骨架蛋白抑制剂、β-arrestin 2 的 siRNA 或从细胞外缓冲液中去除氯化钠可部分减轻 V1B 受体的广泛内化,表明这种内化涉及网格蛋白包被的凹陷。总之,这些结果表明,调节质膜中 V1B 受体数量和亲和力的机制与 V1A 和 V2 受体的相应机制明显不同,并在应激条件下(即血管加压素释放增加时)发挥关键作用。